IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy

Cancer Immunology, Immunotherapy

Volumn 59, Issue 9, 2010, Pages 1325-1334

  Helms, Mike W ^a   Prescher, Jennifer A ^a   Cao, Yu An ^a   Schaffert, Steven ^a   Contag, Christopher H ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Bioluminescence imaging; Cytokine induced killer cells; IL12; In vivo imaging

Indexed keywords

INTERLEUKIN 12;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL CULTURE; CELL EXPANSION; CELL HOMING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DRUG CYTOTOXICITY; DRUG EFFICACY; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SOLID TUMOR;

ANIMALS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-12; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; REMISSION INDUCTION; T-LYMPHOCYTES; TIME FACTORS;

EID: 77955509674     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0860-y     Document Type: Article

References (44)

1. JC Alvarnas YC Linn EG Hope RS Negrin 2001 Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation Biol Blood Marrow Transplant 7 216 222 10.1053/bbmt.2001.v7.pm11349808 11349808 1:CAS:528:DC%2BD3MXjvVaksLY%3D
2. MB Atkins MJ Robertson M Gordon MT Lotze M DeCoste JS DuBois J Ritz AB Sandler HD Edington PD Garzone JW Mier CM Canning L Battiato H Tahara ML Sherman 1997 Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies Clin Cancer Res 3 409 417 9815699 1:CAS:528:DyaK2sXitVKmt7c%3D
3. E Bajetta M Del Vecchio R Mortarini R Nadeau A Rakhit L Rimassa C Fowst A Borri A Anichini G Parmiani 1998 Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma Clin Cancer Res 4 75 85 9516955 1:CAS:528:DyaK1cXmtFSmtw%3D%3D
4. J Baker MR Verneris M Ito JA Shizuru RS Negrin 2001 Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production Blood 97 2923 2931 10.1182/blood.V97.10.2923 11342413 1:CAS:528:DC%2BD3MXjsl2rtL8%3D
5. AD Borowsky R Namba LJT Young KW Hunter JG Hodgson CG Tepper ET McGoldrick WJ Muller R Cardiff JP Gregg 2005 Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior Clin Exp Metastasis 22 47 58 10.1007/s10585-005-2908-5 16132578 1:CAS:528:DC%2BD2MXhtFegtrfF (Pubitemid 41185861)
6. YA Cao MH Bachmann A Beilhack Y Yang M Tanaka RJ Swijnenburg R Reeves C Taylor-Edwards S Schulz TC Doyle CG Fathman RC Robbins LA Herzenberg RS Negrin CH Contag 2005 Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation Transplantation 80 134 139 10.1097/01.TP.0000164347.50559.A3 16003245 (Pubitemid 40980907)
7. YA Cao AJ Wagers A Beilhack J Dusich MH Bachmann RS Negrin IL Weissman CH Contag 2004 Shifting foci of hematopoiesis during reconstitution from single stem cells Proc Natl Acad Sci USA 101 221 226 10.1073/pnas.2637010100 14688412 1:CAS:528:DC%2BD2cXjvFansQ%3D%3D (Pubitemid 38084231)
8. BD Car VM Eng JM Lipman TD Anderson 1999 The toxicology of interleukin-12: a review Toxicol Pathol 27 58 63 10.1177/019262339902700112 10367675 1:CAS:528:DyaK1MXhtlSit7Y%3D
9. F Cavallo P Signorelli M Giovarelli P Musiani A Modesti MJ Brunda MP Colombo G Forni 1997 Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12 J Natl Cancer Inst 89 1049 1058 10.1093/jnci/89.14.1049 9230887 1:CAS:528:DyaK2sXlt1Cks78%3D
10. MP Colombo G Trinchieri 2002 Interleukin-12 in anti-tumor immunity and immunotherapy Cytokine Growth Factor Rev 13 155 168 10.1016/S1359-6101(01)00032- 6 11900991 1:CAS:528:DC%2BD38XitFWhs74%3D (Pubitemid 34229390)
11. M Del Vecchio E Bajetta S Canova MT Lotze A Wesa G Parmiani A Anichini 2007 Interleukin-12: biological properties and clinical application Clin Cancer Res 13 4677 4685 10.1158/1078-0432.CCR-07-0776 17699845 1:CAS:528: DC%2BD2sXptVGmsbY%3D (Pubitemid 47294773)
12. ME Dudley SA Rosenberg 2007 Adoptive cell transfer therapy Semin Oncol 34 524 531 10.1053/j.seminoncol.2007.09.002 18083376 (Pubitemid 350236303)
13. M Edinger YA Cao MR Verneris MH Bachmann CH Contag RS Negrin 2003 Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging Blood 101 640 648 10.1182/blood-2002-06-1751 12393519 1:CAS:528:DC%2BD3sXkvVWqtw%3D%3D (Pubitemid 36077588)
14. L Gattinoni CA Klebanoff DC Palmer C Wrzesinski K Kerstann Z Yu SE Finkelstein MR Theoret SA Rosenberg NP Restifo 2005 Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells J Clin Invest 115 1616 1626 10.1172/JCI24480 15931392 1:CAS:528:DC%2BD2MXkvF2lsro%3D (Pubitemid 40814670)
15. M Giroux F Denis 2005 CD1d-unrestricted human NKT cells release chemokines upon Fas engagement Blood 105 703 710 10.1182/blood-2004-04-1537 15345586 1:CAS:528:DC%2BD2MXltlGnsg%3D%3D (Pubitemid 40070756)
16. JA Gollob KG Veenstra RA Parker JW Mier DF McDermott D Clancy L Tutin H Koon MB Atkins 2003 Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma J Clin Oncol 21 2564 2573 10.1200/JCO.2003.12.119 12829677 1:CAS:528:DC%2BD2cXptlCkt7g%3D (Pubitemid 46606339)
17. L Heinzerling R Dummer J Pavlovic J Schultz G Burg K Moelling 2002 Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice Exp Dermatol 11 232 240 10.1034/j.1600-0625. 2001.110306.x 12102662 1:CAS:528:DC%2BD38XmtVWjtLs%3D (Pubitemid 36934653)
18. M Introna M Franceschetti A Ciocca G Borleri E Conti J Golay A Rambaldi 2006 Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation Bone Marrow Transplant 38 621 627 10.1038/sj.bmt.1705503 16980990 1:CAS:528:DC%2BD28XhtVyktLjF (Pubitemid 44596854)
19. P Lee F Wang J Kuniyoshi V Rubio T Stuges S Groshen C Gee R Lau G Jeffery K Margolin V Marty J Weber 2001 Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma J Clin Oncol 19 3836 3847 11559721 1:CAS:528:DC%2BD3MXnsVKqsbg%3D
20. T Leemhuis S Wells C Scheffold M Edinger RS Negrin 2005 A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma Biol Blood Marrow Transplant 11 181 187 10.1016/j.bbmt.2004.11.019 15744236 (Pubitemid 40287916)
21. R Lenzi M Rosenblum C Verschraegen AP Kudelka JJ Kavanagh ME Hicks EA Lang MA Nash LB Levy ME Garcia CD Platsoucas JL Abbruzzese RS Freedman 2002 Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma Clin Cancer Res 8 3686 3695 12473577 1:CAS:528:DC%2BD38XpslCjtro%3D
22. PH Lu RS Negrin 1994 A novel population of expanded human CD3+ CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency J Immunol 153 1687 1696 7519209 1:CAS:528:DyaK2cXlslOmu7k%3D
23. V Marin E Dander E Biagi M Introna G Fazio A Biondi G D'Amico 2006 Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy Exp Hematol 34 1219 1229 10.1016/j.exphem.2006.05.004 16939815 1:CAS:528: DC%2BD28XovVSrsLk%3D (Pubitemid 44291496)
24. G Mazzolini C Alfaro B Sangro E Feijoo J Ruiz A Benito I Tirapu A Arina J Sola M Herraiz F Lucena C Olague J Subtil J Quiroga I Herrero B Sadaba M Bendandi C Qian J Prieto I Melero 2005 Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas J Clin Oncol 23 999 1010 10.1200/JCO.2005.00.463 15598979 1:CAS:528:DC%2BD2MXit1Gnsr0%3D (Pubitemid 46202319)
25. JJ Mule S Shu SL Schwarz SA Rosenberg 1984 Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2 Science 225 1487 1489 10.1126/science.6332379 6332379 1:STN:280: DyaL2czgtVegsQ%3D%3D
26. R Nishimura J Baker A Beilhack R Zeiser JA Olson EI Sega M Karimi RS Negrin 2008 In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity Blood 112 2563 2574 10.1182/blood-2007-06-092817 18565854 1:CAS:528:DC%2BD1cXhtFCru7rM
27. DJ Powell Jr ME Dudley PF Robbins SA Rosenberg 2005 Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy Blood 105 241 250 10.1182/blood-2004-06-2482 15345595 1:CAS:528:DC%2BD2MXis1Gqug%3D%3D (Pubitemid 40053089)
28. AH Rook GS Wood EK Yoo R Elenitsas DM Kao ML Sherman WK Witmer KA Rockwell RB Shane SR Lessin EC Vonderheid 1999 Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses Blood 94 902 908 10419880 1:CAS:528:DyaK1MXkvFCjurg%3D
29. SA Rosenberg NP Restifo JC Yang RA Morgan ME Dudley 2008 Adoptive cell transfer: a clinical path to effective cancer immunotherapy Nat Rev Cancer 8 299 308 10.1038/nrc2355 18354418 1:CAS:528:DC%2BD1cXjsFCmsLg%3D (Pubitemid 351430867)
30. SA Rosenberg P Spiess R Lafreniere 1986 A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes Science 233 1318 1321 10.1126/science.3489291 3489291 1:STN:280:DyaL28zhsFygsQ%3D%3D
31. SA Rosenberg JR Yannelli JC Yang SL Topalian DJ Schwartzentruber JS Weber DR Parkinson CA Seipp JH Einhorn DE White 1994 Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 J Natl Cancer Inst 86 1159 1166 10.1093/jnci/86.15.1159 8028037 1:STN:280:DyaK2czgtVKgtw%3D%3D
32. IG Schmidt-Wolf S Finke B Trojaneck A Denkena P Lefterova N Schwella HG Heuft G Prange M Korte M Takeya T Dorbic A Neubauer B Wittig D Huhn 1999 Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma Br J Cancer 81 1009 1016 10.1038/sj.bjc.6690800 10576658 1:CAS:528:DyaK1MXnvFSjsL4%3D (Pubitemid 29516145)
33. IG Schmidt-Wolf P Lefterova BA Mehta LP Fernandez D Huhn KG Blume IL Weissman RS Negrin 1993 Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells Exp Hematol 21 1673 1679 7694868 1:STN:280:DyaK2c%2Fmt12ltw%3D%3D
34. IG Schmidt-Wolf RS Negrin HP Kiem KG Blume IL Weissman 1991 Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity J Exp Med 174 139 149 10.1084/jem.174.1.139 1711560 1:CAS:528:DyaK3MXltFamsbY%3D
35. SH Thorne RS Negrin CH Contag 2006 Synergistic antitumor effects of immune cell-viral biotherapy Science 311 1780 1784 10.1126/science.1121411 16556847 1:CAS:528:DC%2BD28Xis1equr8%3D
36. K Tsung JB Meko YL Tsung GR Peplinski JA Norton 1998 Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12 J Immunol 160 1369 1377 9570556 1:CAS:528:DyaK1cXnslWksg%3D%3D
37. MR Verneris M Ito J Baker A Arshi RS Negrin JA Shizuru 2001 Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8 + NK-T cells in the treatment of lymphoma Biol Blood Marrow Transplant 7 532 542 10.1016/S1083-8791(01)70014-6 11760085 1:STN:280: DC%2BD38%2Fjt1Slsw%3D%3D
38. MR Verneris M Karami J Baker A Jayaswal RS Negrin 2004 Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells Blood 103 3065 3072 10.1182/blood-2003-06-2125 15070686 1:CAS:528:DC%2BD2cXjsVags70%3D (Pubitemid 38451682)
39. HJ Wajchman CW Pierce VA Varma MM Issa J Petros KE Dombrowski 2004 Ex vivo expansion of CD8+ CD56+ and CD8+ Cancer Res 64 1171 1180 10.1158/0008-5472.CAN-3254-2 14871854 1:CAS:528:DC%2BD2cXhtFCgt74%3D (Pubitemid 38176926)
40. GR Weiss MA O'Donnell K Loughlin K Zonno RJ Laliberte ML Sherman 2003 Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder J Immunother 26 343 348 10.1097/00002371-200307000- 00006 12843796 1:CAS:528:DC%2BD3sXmt1Omsr4%3D (Pubitemid 36858718)
41. JM Weiss JJ Subleski JM Wigginton RH Wiltrout 2007 Immunotherapy of cancer by IL-12-based cytokine combinations Expert Opin Biol Ther 7 1705 1721 10.1517/14712598.7.11.1705 17961093 1:CAS:528:DC%2BD2sXht1ams73L (Pubitemid 350157496)
42. DS Weng J Zhou QM Zhou M Zhao QJ Wang LX Huang YQ Li SP Chen PH Wu JC Xia 2008 Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas J Immunother 31 63 71 10.1097/CJI.0b013e31815a121b 18157013 (Pubitemid 351619405)
43. B Zoll P Lefterova M Csipai S Finke B Trojaneck O Ebert B Micka K Roigk M Fehlinger GD Schmidt-Wolf D Huhn IG Schmidt-Wolf 1998 Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12 Cancer Immunol Immunother 47 221 226 10.1007/s002620050524 9875675 1:CAS:528: DyaK1MXmslSlsg%3D%3D (Pubitemid 29009677)
44. B Zoll P Lefterova O Ebert D Huhn A Von Ruecker IG Schmidt-Wolf 2000 Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation Cytokine 12 1385 1390 10.1006/cyto.2000.0733 10975999 1:CAS:528:DC%2BD3cXmt1aitbo%3D